NuCana Q2 loss narrows as clinical milestones remain on track
NuCana Q2 loss narrows as clinical milestones remain on track
Overview
UK cancer drug developer's Q2 net loss narrowed to £3.1 mln from £24.1 mln yr/yr
Company ended Q2 with £19.5 mln in cash, expects runway to 2029
Completed Phase 2 recruitment for NUC-7738, final data expected later in 2026
Outlook
NuCana expects to announce final data from Phase 2 NUC-7738 study later in 2026
Company anticipates cash resources will fund operations into 2029
NuCana plans to seek FDA guidance on registrational strategy for NUC-7738 in melanoma
Result Drivers
CLINICAL PROGRESS - Co completed patient recruitment for NUC-7738 Phase 2 expansion study in PD-1 inhibitor-resistant melanoma
PIPELINE ADVANCEMENT - Co continues to assess additional indications and combination strategies for NUC-7738 and NUC-3373
FINANCIAL FLEXIBILITY - Cash resources expected to fund operations into 2029, supporting continued pipeline development
Company press release: ID:nGNX2DZGrd
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 EPS |
| GBP 0 |
|
Q2 Net Loss |
| GBP 3.08 mln |
|
Q2 Operating Income |
| -GBP 3.55 mln |
|
Q2 Pretax Loss |
| GBP 3.41 mln |
|
Reuters Recommended Reads
Aug 10 - Biotech firm Nkarta posts Q2 net loss; cash runway into 2029
Aug 13 - Pyxis Oncology Q2 loss widens on increased administrative costs
Aug 11 - Oncology firm Immunome's Q2 net loss widens as R&D costs rise
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)